方鸿, 肖露蓉, 宫雪. 超声引导下注射聚桂醇硬化治疗肝肾囊肿的临床效果[J]. 实用临床医药杂志, 2019, 23(12): 5-7. DOI: 10.7619/jcmp.201912002
引用本文: 方鸿, 肖露蓉, 宫雪. 超声引导下注射聚桂醇硬化治疗肝肾囊肿的临床效果[J]. 实用临床医药杂志, 2019, 23(12): 5-7. DOI: 10.7619/jcmp.201912002
FANG Hong, XIAO Lurong, GONG Xue. Clinical effect of sclerotherapy by ultrasound-guided injection of lauromacrogol for hepatic and renal cysts[J]. Journal of Clinical Medicine in Practice, 2019, 23(12): 5-7. DOI: 10.7619/jcmp.201912002
Citation: FANG Hong, XIAO Lurong, GONG Xue. Clinical effect of sclerotherapy by ultrasound-guided injection of lauromacrogol for hepatic and renal cysts[J]. Journal of Clinical Medicine in Practice, 2019, 23(12): 5-7. DOI: 10.7619/jcmp.201912002

超声引导下注射聚桂醇硬化治疗肝肾囊肿的临床效果

Clinical effect of sclerotherapy by ultrasound-guided injection of lauromacrogol for hepatic and renal cysts

  • 摘要:
      目的  探讨超声引导下注射聚桂醇硬化治疗肝肾囊肿的疗效及其不良反应。
      方法  对68例肝肾囊肿患者(69个囊肿)在超声引导下注射聚桂醇硬化治疗,术后1、3、6个月随访期间观察囊肿体积的变化及疗效。
      结果  68例患者均穿刺成功。1月后复查全部囊肿均缩小50%以上, 3月后27个囊肿消失, 6月后65个消失或几乎消失。本组囊肿治疗有效率为100.0%, 治愈率为94.2%。63例患者无明显不良反应,其余5例中,其中3例患者术后有轻微灼烧感, 2例患者出现术后低热反应。
      结论  聚桂醇作为肝肾囊肿硬化治疗的一种新型硬化剂,治愈率高,疗效确切,且不良反应较少。

     

    Abstract:
      Objective  To investigate the efficacy and adverse reactions of ultrasound-guided injection of lauromacrogol in the treatment of hepatorenal cyst.
      Methods  A total of 68 patients (69 cysts) with hepatorenal cyst were treated with sclerotherapy by ultrasound-guided injection of lauromacrogol. Changes in cyst volume and its efficacy during follow-up at 1, 3, and 6 months after surgery were observed.
      Results  All the 68 patients were successfully punctured, and all the cysts were reduced by more than 50% after 1 month. A total of 27 cysts disappeared after 3 months of treatment, and 65 disappeared or nearly disappeared after 6 months. The effective rate was 100.0% and the cure rate was 94.2%. There were no obvious adverse reactions in 63 patients. Out of the rest 5 patients, mild burning sensation occurred in 3 patients and low postoperative fever in 2 patients.
      Conclusion  Lauromacrogol, as a new type of hardeners for hepatorenal cyst, had significantly lower adverse reactions, better cure rate and definite curative efficacy.

     

/

返回文章
返回